Telehealth company Ro will offer single-dose vials of Eli Lilly's obesity therapy Zepbound in an expansion of the ways patients with a prescription can access the drug. The agreement means Ro has ...

Eli Lilly has launched new single-dose 2.5mg and 5.0mg vials of its obesity drug Zepbound in a move that it said would make it easier for people paying for the drug out-of-pocket to afford treatment.

Eli Lilly and Sarepta Therapeutics have been growing their sales at a good clip. Eli Lilly has a vast portfolio of approved treatments and a deep pipeline of candidates. Sarepta Therapeutics ...

This surge was largely driven by its blockbuster GLP-1 receptor agonists, Mounjaro and Zepbound, which dominate the obesity and diabetes markets. Eli Lilly’s net income doubled compared to Q4 ...

Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) approved Zepbound® (tirzepatide) as the first and only prescription medicine for adults with moderate ...

He later switched to Mounjaro, from Eli Lilly, which is sold as Zepbound for obesity. He lost 30 percent of his weight and got his blood sugar under control. Now, he said, he’s “feeling better ...

The Philadelphia Flyers made a big move late last month when they traded Morgan Frost and Joel Farabee to the Calgary Flames in exchange for Andrei Kuzmenko, Jakob Pelletier, a 2025 second-round ...

The Philadelphia Flyers have announced that Emil Andrae, Rodrigo Abols, and Jacob Gaucher have been assigned to their AHL affiliate, the Lehigh Valley Phantoms. With the 4 Nations Face-Off break ...

Eli Lilly, the manufacturer of Mounjaro and Zepbound, did not immediately respond to a request for comment. While reports of vision problems in patients taking semaglutide and tirzepatide are rare ...

Boris Becker's ex-wife Lilly has won the German version of I'm A Celebrity... Get Me Out Of Here! after stealing the hearts of the nation. The former Wimbledon tennis star, 57, has endured a ...

Eli Lilly and Company (NYSE ... driven by strong volume growth from Mounjaro and Zepbound. Earnings per share (EPS) for the quarter doubled, rising 102% to $4.88 on a reported basis.

and Zepbound (tirzepatide), produced by Fortune 500 firm Eli Lilly & Co. As demand for these medications has soared in recent years, periodic shortages prompted companies like Hims & Hers to step ...